Literature DB >> 24041577

Autocrine TNF-α production supports CML stem and progenitor cell survival and enhances their proliferation.

Paolo Gallipoli1, Francesca Pellicano, Heather Morrison, Kamilla Laidlaw, Elaine K Allan, Ravi Bhatia, Mhairi Copland, Heather G Jørgensen, Tessa L Holyoake.   

Abstract

Chronic myeloid leukemia (CML) stem cells are not dependent on BCR-ABL kinase for their survival, suggesting that kinase-independent mechanisms must contribute to their persistence. We observed that CML stem/progenitor cells (SPCs) produce tumor necrosis factor-α (TNF-α) in a kinase-independent fashion and at higher levels relative to their normal counterparts. We therefore investigated the role of TNF-α and found that it supports survival of CML SPCs by promoting nuclear factor κB/p65 pathway activity and expression of the interleukin 3 and granulocyte/macrophage-colony stimulating factor common β-chain receptor. Furthermore, we demonstrate that in CML SPCs, inhibition of autocrine TNF-α signaling via a small-molecule TNF-α inhibitor induces apoptosis. Moreover TNF-α inhibition combined with nilotinib induces significantly more apoptosis relative to either treatment alone and a reduction in the absolute number of primitive quiescent CML stem cells. These results highlight a novel survival mechanism of CML SPCs and suggest a new putative therapeutic target for their eradication.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24041577      PMCID: PMC3953090          DOI: 10.1182/blood-2013-02-485607

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  25 in total

1.  TNFα facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms.

Authors:  Angela G Fleischman; Karl J Aichberger; Samuel B Luty; Thomas G Bumm; Curtis L Petersen; Shirin Doratotaj; Kavin B Vasudevan; Dorian H LaTocha; Fei Yang; Richard D Press; Marc M Loriaux; Heike L Pahl; Richard T Silver; Anupriya Agarwal; Thomas O'Hare; Brian J Druker; Grover C Bagby; Michael W Deininger
Journal:  Blood       Date:  2011-08-22       Impact factor: 22.113

2.  Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia.

Authors:  X Jiang; A Lopez; T Holyoake; A Eaves; C Eaves
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-26       Impact factor: 11.205

3.  ADAR1 promotes malignant progenitor reprogramming in chronic myeloid leukemia.

Authors:  Qingfei Jiang; Leslie A Crews; Christian L Barrett; Hye-Jung Chun; Angela C Court; Jane M Isquith; Maria A Zipeto; Daniel J Goff; Mark Minden; Anil Sadarangani; Jessica M Rusert; Kim-Hien T Dao; Sheldon R Morris; Lawrence S B Goldstein; Marco A Marra; Kelly A Frazer; Catriona H M Jamieson
Journal:  Proc Natl Acad Sci U S A       Date:  2012-12-28       Impact factor: 11.205

4.  Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease.

Authors:  Jean-Claude Chomel; Marie-Laure Bonnet; Nathalie Sorel; Angelina Bertrand; Marie-Claude Meunier; Serge Fichelson; Michael Melkus; Annelise Bennaceur-Griscelli; François Guilhot; Ali G Turhan
Journal:  Blood       Date:  2011-07-25       Impact factor: 22.113

5.  Potentiation of early hematopoiesis by tumor necrosis factor-alpha is followed by inhibition of granulopoietic differentiation and proliferation.

Authors:  C Caux; C Favre; S Saeland; V Duvert; I Durand; P Mannoni; J Banchereau
Journal:  Blood       Date:  1991-08-01       Impact factor: 22.113

6.  A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation.

Authors:  J Y Reuther; G W Reuther; D Cortez; A M Pendergast; A S Baldwin
Journal:  Genes Dev       Date:  1998-04-01       Impact factor: 11.361

7.  Cellular proliferation and activation of NF kappa B are induced by autocrine production of tumor necrosis factor alpha in the human T lymphoma line HuT 78.

Authors:  M A O'Connell; R Cleere; A Long; L A O'Neill; D Kelleher
Journal:  J Biol Chem       Date:  1995-03-31       Impact factor: 5.157

8.  IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer.

Authors:  Sergei Grivennikov; Eliad Karin; Janos Terzic; Daniel Mucida; Guann-Yi Yu; Sivakumar Vallabhapurapu; Jürgen Scheller; Stefan Rose-John; Hilde Cheroutre; Lars Eckmann; Michael Karin
Journal:  Cancer Cell       Date:  2009-02-03       Impact factor: 31.743

9.  Altered microenvironmental regulation of leukemic and normal stem cells in chronic myelogenous leukemia.

Authors:  Bin Zhang; Yin Wei Ho; Qin Huang; Takahiro Maeda; Allen Lin; Sung-Uk Lee; Alan Hair; Tessa L Holyoake; Claudia Huettner; Ravi Bhatia
Journal:  Cancer Cell       Date:  2012-04-17       Impact factor: 31.743

10.  Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival.

Authors:  Ashley Hamilton; G Vignir Helgason; Mirle Schemionek; Bin Zhang; Svetlana Myssina; Elaine K Allan; Franck E Nicolini; Carsten Müller-Tidow; Ravi Bhatia; Valerie G Brunton; Steffen Koschmieder; Tessa L Holyoake
Journal:  Blood       Date:  2011-12-19       Impact factor: 22.113

View more
  43 in total

1.  Chronic myeloid leukemia stem cells require cell-autonomous pleiotrophin signaling.

Authors:  Heather A Himburg; Martina Roos; Tiancheng Fang; Yurun Zhang; Christina M Termini; Lauren Schlussel; Mindy Kim; Amara Pang; Jenny Kan; Liman Zhao; Hyung Suh; Joshua P Sasine; Gopal Sapparapu; Peter M Bowers; Gary Schiller; John P Chute
Journal:  J Clin Invest       Date:  2020-01-02       Impact factor: 14.808

2.  Ruxolitinib induces autophagy in chronic myeloid leukemia cells.

Authors:  Bakiye Goker Bagca; Ozgun Ozalp; Cansu Caliskan Kurt; Zeynep Mutlu; Guray Saydam; Cumhur Gunduz; Cigir Biray Avci
Journal:  Tumour Biol       Date:  2015-08-23

Review 3.  Novel approaches to therapy in CML.

Authors:  Ravi Bhatia
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

4.  TGF-α and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapy.

Authors:  E Nievergall; J Reynolds; C H Kok; D B Watkins; M Biondo; S J Busfield; G Vairo; K Fuller; W N Erber; T Sadras; R Grose; D T Yeung; A F Lopez; D K Hiwase; T P Hughes; D L White
Journal:  Leukemia       Date:  2016-02-22       Impact factor: 11.528

5.  IL-33 signaling contributes to the pathogenesis of myeloproliferative neoplasms.

Authors:  Lukas F Mager; Carsten Riether; Christian M Schürch; Yara Banz; Marie-Hélène Wasmer; Regula Stuber; Alexandre P Theocharides; Xiaohong Li; Yu Xia; Hirohisa Saito; Susumu Nakae; Gabriela M Baerlocher; Markus G Manz; Kathy D McCoy; Andrew J Macpherson; Adrian F Ochsenbein; Bruce Beutler; Philippe Krebs
Journal:  J Clin Invest       Date:  2015-05-26       Impact factor: 14.808

Review 6.  What's different about atypical CML and chronic neutrophilic leukemia?

Authors:  Kim-Hien T Dao; Jeffrey W Tyner
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2015

7.  The impact of inflammation and cytokine expression of PM2.5 in AML.

Authors:  Tingting Chen; Juan Zhang; Hui Zeng; Yue Zhang; Yong Zhang; Xiaohuan Zhou; Dong Zhao; Yingmei Feng; Hebing Zhou
Journal:  Oncol Lett       Date:  2018-06-13       Impact factor: 2.967

8.  Tumor necrosis factor alpha promotes the proliferation of human nucleus pulposus cells via nuclear factor-κB, c-Jun N-terminal kinase, and p38 mitogen-activated protein kinase.

Authors:  Xiao-Hu Wang; Xin Hong; Lei Zhu; Yun-Tao Wang; Jun-Ping Bao; Lei Liu; Feng Wang; Xiao-Tao Wu
Journal:  Exp Biol Med (Maywood)       Date:  2014-10-10

Review 9.  Interplay between inflammatory tumor microenvironment and cancer stem cells.

Authors:  Shijian Zhang; Xi Yang; Lei Wang; Chenping Zhang
Journal:  Oncol Lett       Date:  2018-05-16       Impact factor: 2.967

10.  A 'telomere-associated secretory phenotype' cooperates with BCR-ABL to drive malignant proliferation of leukemic cells.

Authors:  M Braig; N Pällmann; M Preukschas; D Steinemann; W Hofmann; A Gompf; T Streichert; T Braunschweig; M Copland; K L Rudolph; C Bokemeyer; S Koschmieder; A Schuppert; S Balabanov; T H Brümmendorf
Journal:  Leukemia       Date:  2014-03-07       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.